WuXi AppTec
2025.05.02
05:23
The Hang Seng Biotech Index continued to expand its gains in the afternoon, with WuXi AppTec (02359.HK) rising nearly 8% and WuXi Biologics (02269.HK) rising more than 6%.
2025.04.30
01:21
Hong Kong stocks opened, the Hang Seng Index opened up 0.14%, the Tech Index opened up 0.21%. WuXi AppTec (02359.HK) rose more than 3%, and China Merchants Bank (03968.HK) fell more than 1% after the results.
2025.04.29
02:17
WuXi AppTec rose more than 5%, and the Biopharmaceutical ETF (159839) held 12.31% of the stock
WuXi AppTec's share price increase expanded to 5.08%. The Biopharmaceutical ETF (159839) holds 12.31% of the stock. The current increase is 0.94%, with a turnover of 6.449 million yuan and an increase of 273 million shares in the past month.
02:14
Hong Kong stocks rose, with the Hang Seng Index up more than 1%
Hong Kong stocks rose, with the Hang Seng Index up more than 1% and the Hang Seng Technology Index up nearly 2%. Innovative drugs and retail stocks led the gains. Leapmotor and WuXi AppTec rose more than 7%.
01:26
Hong Kong-listed WuXi AppTec (02359.HK) rose more than 5%, with a net profit of 3.672 billion yuan in the first quarter, a year-on-year increase of 89.06%.
01:21
Hong Kong stocks opened: Hang Seng Index opened 0.46% higher, Hang Seng Technology Index opened 0.67% higher
Hong Kong stocks opened, the Hang Seng Index opened 0.46% higher, and the Hang Seng Technology Index opened 0.67% higher. WuXi AppTec opened 5% higher, and the company's net profit in the first quarter was about 3.672 billion yuan, an increase of 89.06% year-on-year. CIMC opened 4.7% higher, and the company's net profit in the first quarter was 544 million yuan, an increase of 550.21% year-on-year. NIO-SW rose more than 5.5%, and Citigroup included the company's stock in the 30-day "positive catalyst watch" list.
2025.04.28
09:07
WuXi AppTec: Net profit in the first quarter of 2025 was 3.672 billion yuan, a year-on-year increase of 89.06%
WuXi AppTec announced that its operating revenue in the first quarter of 2025 was 9.655 billion yuan, a year-on-year increase of 20.96%; net profit attributable to shareholders of the listed company was 3.672 billion yuan, a year-on-year increase of 89.06%; net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 2.329 billion yuan, a year-on-year increase of 14.50%; net cash flow from operating activities was 3.195 billion yuan, a year-on-year increase of 41.57%; basic earnings per share was 1.29 yuan per share, a year-on-year increase of 92.54%; diluted earnings per share was 1.28 yuan per share, a year-on-year increase of 93.94%; the weighted average return on equity was 6.08%, an increase of 2.57 percentage points.
2025.04.17
09:19
Information from the Hong Kong Stock Exchange shows that UBS Group's holdings in WuXi AppTec's (02359.HK) H shares have fallen from 7.39% on April 11 to 6.72%.
2025.04.16
09:13
UBS increases stake in WuXi AppTec H shares
Data from the Hong Kong Stock Exchange showed that UBS Group increased its long position in WuXi AppTec's H shares from 6.73% to 7.30% on April 10.
2025.04.15
07:34
The Hong Kong stock market's biopharmaceutical sector continued to weaken, with Tiger Pharmaceuticals (03347.HK) falling more than 4%, BeiGene (06160.HK) falling more than 2%, and WuXi AppTec (02359.HK) and others following suit.
2025.04.14
08:58
WuXi AppTec (02359.HK): The company announced that it will hold a board meeting on April 28, 2025 (Monday) to consider and approve (among other things) the Group's first quarter results for the three months ended March 31, 2025 and their release.
01:45
The Hong Kong stock market's biopharmaceutical sector strengthened in early trading, with Zai Lab (09688.HK) rising more than 12%, Junshi Biosciences (01877.HK) rising more than 5%, and BeiGene (06160.HK), WuXi AppTec (02359.HK) and others following suit.
2025.04.10
03:19
WuXi AppTec: The U.S. National Security Commission on Emerging Biotechnologies report is far-fetched and unfounded
At the WuXi AppTec 2024 performance briefing held today, the company's vice chairman and global chief investment officer Hu Zhengguo said, "We have noticed that the recent U.S. National Security Commission on Emerging Biotechnologies report contains several far-fetched and unfounded allegations involving the company. The company has previously stated publicly that it has never transferred any U.S. customer data or intellectual property to a third party without authorization. We have also communicated with relevant U.S. government agencies to clarify the facts." Note: Recently, the U.S. National Security Commission on Emerging Biotechnologies stated in a radical 215-page report that China's leading biopharmaceutical company WuXi AppTec is "deeply embedded in the U.S. biopharmaceutical supply chain."
02:51
WuXi AppTec responds to the impact of the US plan to impose tariffs on drugs: The impact is still very unclear, and the company's full-year guidance is maintained for the time being
At the WuXi AppTec earnings conference held on April 10, WuXi AppTec Vice Chairman and Global Chief Investment Officer Hu Zhengguo responded to a question from a Cailian reporter who asked as an investor about "the US plan to impose tariffs on drugs" and said: "Tariffs will definitely have an impact on the company, but the extent of the impact is still unclear." He also said that the company's full-year (performance) guidance will be maintained for the time being, while closely monitoring the progress of tariff policies and the impact on the guidance.
02:07
Hong Kong pharmaceutical stocks rebound
Hong Kong-listed pharmaceutical stocks rebounded, with Zhaoyan Pharmaceutical, WuXi AppTec, WuXi Biologics, and Corning Life Sciences rising by more than 7%.
Load More
Email Subscription
Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.
Weekly Highlights
Important events and data forecast for next week - China's foreign exchange reserves, trade account, CPI data, interest rate decisions of the Bank of England and the United States

2025-05-04

Donghua Software: Donghua Fast and Laibin Sugar Bureau jointly promote sugar industry AI big model

2025-05-06

Innovative drug concepts continue to adjust BeiGene's stock price fell nearly 9%

2025-05-07

Southbound funds sold a large amount of 7.866 billion yuan today. In terms of Hong Kong Stock Connect (Shanghai), Tencent Holdings and Xiaomi Group-W received net sales of HK$2.543 billion and HK$1.686 billion respectively; China Construction Bank ranked first in net purchase amount, with an amount of HK$668 million; in terms of Hong Kong Stock Connect (Shenzhen), SMIC and Xiaomi Group-W received net sales of HK$443 million and HK$341 million respectively; Meituan-W ranked first in net purchase amount, with an amount of HK$121 million.

2025-05-07

Australia's AIG/PWC Performance of Manufacturing Index in April was -26.5, compared with -29.7 in the previous month.

2025-05-07

ASIA TECH WIRE

Grasp technology trends

Download